JP2019515010A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019515010A5 JP2019515010A5 JP2018559826A JP2018559826A JP2019515010A5 JP 2019515010 A5 JP2019515010 A5 JP 2019515010A5 JP 2018559826 A JP2018559826 A JP 2018559826A JP 2018559826 A JP2018559826 A JP 2018559826A JP 2019515010 A5 JP2019515010 A5 JP 2019515010A5
- Authority
- JP
- Japan
- Prior art keywords
- therapeutic agent
- amino
- phenyl
- methylureido
- dimethoxyphenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 claims 27
- 229940124597 therapeutic agent Drugs 0.000 claims 26
- 150000003839 salts Chemical class 0.000 claims 18
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 claims 14
- 229940121647 egfr inhibitor Drugs 0.000 claims 14
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 13
- XNRVGTHNYCNCFF-UHFFFAOYSA-N Lapatinib ditosylate monohydrate Chemical compound O.CC1=CC=C(S(O)(=O)=O)C=C1.CC1=CC=C(S(O)(=O)=O)C=C1.O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 XNRVGTHNYCNCFF-UHFFFAOYSA-N 0.000 claims 6
- -1 ethylpiperazin-1-yl Chemical group 0.000 claims 6
- 239000002136 L01XE07 - Lapatinib Substances 0.000 claims 5
- MBWRLLRCTIYXDW-UHFFFAOYSA-N N-[2-[[6-[(2,6-dichloro-3,5-dimethoxyphenyl)carbamoyl-methylamino]pyrimidin-4-yl]amino]-5-(4-ethylpiperazin-1-yl)phenyl]prop-2-enamide Chemical compound ClC1=C(C(=C(C=C1OC)OC)Cl)NC(N(C)C1=CC(=NC=N1)NC1=C(C=C(C=C1)N1CCN(CC1)CC)NC(C=C)=O)=O MBWRLLRCTIYXDW-UHFFFAOYSA-N 0.000 claims 5
- 229960004891 lapatinib Drugs 0.000 claims 5
- 229960001686 afatinib Drugs 0.000 claims 4
- ULXXDDBFHOBEHA-CWDCEQMOSA-N afatinib Chemical group N1=CN=C2C=C(O[C@@H]3COCC3)C(NC(=O)/C=C/CN(C)C)=CC2=C1NC1=CC=C(F)C(Cl)=C1 ULXXDDBFHOBEHA-CWDCEQMOSA-N 0.000 claims 4
- 229960005395 cetuximab Drugs 0.000 claims 4
- 238000000338 in vitro Methods 0.000 claims 3
- 239000005411 L01XE02 - Gefitinib Substances 0.000 claims 2
- 230000004663 cell proliferation Effects 0.000 claims 2
- 230000003833 cell viability Effects 0.000 claims 2
- 239000012458 free base Substances 0.000 claims 2
- 229960002584 gefitinib Drugs 0.000 claims 2
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical group C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 claims 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 2
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 claims 2
- ULXXDDBFHOBEHA-ONEGZZNKSA-N Afatinib Chemical compound N1=CN=C2C=C(OC3COCC3)C(NC(=O)/C=C/CN(C)C)=CC2=C1NC1=CC=C(F)C(Cl)=C1 ULXXDDBFHOBEHA-ONEGZZNKSA-N 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 claims 1
- DRYRBWIFRVMRPV-UHFFFAOYSA-N quinazolin-4-amine Chemical group C1=CC=C2C(N)=NC=NC2=C1 DRYRBWIFRVMRPV-UHFFFAOYSA-N 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022127803A JP2022160654A (ja) | 2016-05-10 | 2022-08-10 | 細胞生存性及び／又は細胞増殖を低減するための薬物の組み合わせ |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662334102P | 2016-05-10 | 2016-05-10 | |
| US62/334,102 | 2016-05-12 | ||
| PCT/US2017/031771 WO2017196854A1 (en) | 2016-05-10 | 2017-05-09 | Drug combinations for reducing cell viability and/or cell proliferation |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022127803A Division JP2022160654A (ja) | 2016-05-10 | 2022-08-10 | 細胞生存性及び／又は細胞増殖を低減するための薬物の組み合わせ |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019515010A JP2019515010A (ja) | 2019-06-06 |
| JP2019515010A5 true JP2019515010A5 (https=) | 2020-06-18 |
| JP7372740B2 JP7372740B2 (ja) | 2023-11-01 |
Family
ID=58745397
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018559826A Active JP7372740B2 (ja) | 2016-05-10 | 2017-05-09 | 細胞生存性及び／又は細胞増殖を低減するための薬物の組み合わせ |
| JP2022127803A Pending JP2022160654A (ja) | 2016-05-10 | 2022-08-10 | 細胞生存性及び／又は細胞増殖を低減するための薬物の組み合わせ |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022127803A Pending JP2022160654A (ja) | 2016-05-10 | 2022-08-10 | 細胞生存性及び／又は細胞増殖を低減するための薬物の組み合わせ |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US11357769B2 (https=) |
| EP (1) | EP3454898B1 (https=) |
| JP (2) | JP7372740B2 (https=) |
| WO (2) | WO2017196854A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA51570A (fr) * | 2018-01-10 | 2020-11-18 | Eisai R&D Man Co Ltd | Polythérapies pour le traitement du carcinome hépatocellulaire |
| JP2023533903A (ja) * | 2020-05-15 | 2023-08-07 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | Ｆｇｆｒ４阻害剤の経口製剤によるがんの治療方法 |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4679363A (en) * | 1986-01-28 | 1987-07-14 | Adams George W | Township, city and regional land arrangement |
| AU763839B2 (en) | 1998-05-26 | 2003-07-31 | Warner-Lambert Company | Bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation |
| MXPA06001098A (es) | 2003-07-29 | 2006-04-24 | Irm Llc | Compuestos y composiciones utiles como inhibidores de proteina cinasa. |
| GB0512324D0 (en) | 2005-06-16 | 2005-07-27 | Novartis Ag | Organic compounds |
| WO2006038112A1 (en) | 2004-10-01 | 2006-04-13 | Warner-Lambert Company Llc | Use of kinase inhibitors to promote neochondrogenesis |
| BRPI0620408B8 (pt) | 2005-12-21 | 2021-05-25 | Novartis Ag | derivados de pirimidinil aril uréia sendo inibidores de fgf, seus usos, e preparação farmacêutica |
| EP1918376A1 (en) | 2006-11-03 | 2008-05-07 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | FGFR4 promotes cancer cell resistance in response to chemotherapeutic drugs |
| EP2182958A1 (en) * | 2007-07-25 | 2010-05-12 | Alma Mater Studiorum -Universita' di Bologna | Pharmaceutical composition and pharmaceutical kit for the treatment of hepatocellular carcinoma |
| US20090062320A1 (en) | 2007-08-28 | 2009-03-05 | Vito Guagnano | Method of Treating Disorders Mediated by the Fibroblast Growth Factor Receptor |
| TWI546290B (zh) | 2008-06-27 | 2016-08-21 | 賽基艾維洛米斯研究股份有限公司 | 雜芳基化合物及其用途 |
| EP2169071A1 (en) | 2008-09-29 | 2010-03-31 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Rodent cancer model for human FGFR4 Arg388 polymorphism |
| AR079257A1 (es) | 2009-12-07 | 2012-01-04 | Novartis Ag | Formas cristalinas de 3-(2,6-dicloro-3-5-dimetoxi-fenil)-1-{6-[4-(4-etil-piperazin-1-il)-fenil-amino]-pirimidin-4-il}-1-metil-urea y sales de las mismas |
| US9180127B2 (en) | 2009-12-29 | 2015-11-10 | Dana-Farber Cancer Institute, Inc. | Type II Raf kinase inhibitors |
| BR112012016992A2 (pt) | 2010-01-14 | 2019-09-24 | Univ Yale | "funcionalidade que se liga a uma interface de contato assimétrico de um recpetor de tirosina quinase (rtk), hibridoma, composição farmacêutica, uso de uma quantidade efixaz da funcionalidade, método para identificar uma funcionalidade que se liga a uma interface de contato assimétrico de um receptor de tirosina quinase (rtk), e, molécula pequena". |
| WO2011153553A2 (en) | 2010-06-04 | 2011-12-08 | The Regents Of The University Of California | Methods and compositions for kinase inhibition |
| US20140051662A1 (en) | 2011-04-08 | 2014-02-20 | Ab Science | Treatment of multiple myeloma with masitinib |
| CN102816162B (zh) | 2011-06-10 | 2016-04-27 | 中国科学院广州生物医药与健康研究院 | 嘧啶并嘧啶酮类化合物及其药用组合物和应用 |
| CN103106630A (zh) * | 2011-11-10 | 2013-05-15 | 李红彬 | 生态城市规划 |
| US20130183294A1 (en) | 2012-01-18 | 2013-07-18 | Genentech, Inc. | Methods of using fgf19 modulators |
| EA026953B1 (ru) | 2012-02-28 | 2017-06-30 | Астеллас Фарма Инк. | Азотсодержащее ароматическое гетероциклическое соединение |
| CN103306509A (zh) * | 2012-03-06 | 2013-09-18 | 李尚喜 | 未来城市区域定向建设与施工 |
| RU2496937C1 (ru) * | 2012-03-12 | 2013-10-27 | Лев Иванович Гаранин | Способ обустройства антарктиды |
| SMT202100451T1 (it) | 2012-07-11 | 2021-09-14 | Blueprint Medicines Corp | Inibitori del recettore di crescita dei fibroblasti |
| JP2016518316A (ja) | 2013-03-15 | 2016-06-23 | セルジーン アビロミクス リサーチ， インコーポレイテッド | Ｍｋ２阻害剤およびそれらの使用 |
| EP3019491A4 (en) | 2013-07-09 | 2016-12-21 | Dana Farber Cancer Inst Inc | KINASEHEMMER FOR THE TREATMENT OF DISEASES |
| AR097455A1 (es) | 2013-08-28 | 2016-03-16 | Astellas Pharma Inc | Composición farmacéutica que contiene compuesto de pirimidina como un ingrediente activo |
| MX378288B (es) | 2013-10-18 | 2025-03-10 | Eisai R&D Man Co Ltd | Inhibidores de pirimidina del fgfr4. |
| CA2928042C (en) | 2013-10-25 | 2022-05-10 | Blueprint Medicines Corporation | Inhibitors of the fibroblast growth factor receptor |
| WO2015108992A1 (en) | 2014-01-15 | 2015-07-23 | Blueprint Medicines Corporation | Heterobicyclic compounds and their use as fgfr4 receptor inhibitors |
| MA38393B1 (fr) | 2014-03-13 | 2018-11-30 | Sanofi Sa | Composés hétéroaryle et utilisations associées |
| CN104099840B (zh) * | 2014-07-28 | 2016-07-13 | 池昭新 | 一种添加自然地貌的城镇规划模式 |
| SG10201810057UA (en) | 2015-04-14 | 2018-12-28 | Eisai R&D Man Co Ltd | Crystalline fgfr4 inhibitor compound and uses thereof |
| CN113234072B (zh) | 2016-05-20 | 2022-11-04 | 江苏豪森药业集团有限公司 | Fgfr4抑制剂、其制备方法和应用 |
| JP6667014B2 (ja) | 2016-05-20 | 2020-03-18 | 浙江海正薬業股▲ふん▼有限公司Ｚｈｅｊｉａｎｇ Ｈｉｓｕｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌ ＣＯ．，ＬＴＤ． | ピリミジン誘導体、その調製方法および医療での使用 |
-
2017
- 2017-05-09 EP EP17725014.9A patent/EP3454898B1/en active Active
- 2017-05-09 WO PCT/US2017/031771 patent/WO2017196854A1/en not_active Ceased
- 2017-05-09 US US16/300,313 patent/US11357769B2/en active Active
- 2017-05-09 JP JP2018559826A patent/JP7372740B2/ja active Active
- 2017-05-12 WO PCT/US2017/032343 patent/WO2017197226A1/en not_active Ceased
-
2022
- 2022-08-10 JP JP2022127803A patent/JP2022160654A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP4563150A3 (en) | New crystalline forms of n-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methvlphenyl)-2(trifluoromethyl) isonicotinamide as raf inhibitors for the treatment of cancer | |
| NO20065638L (no) | Formuleringer med kontrollert frigivelse inneholdende vardenafil | |
| JP2018109022A5 (https=) | ||
| JP6892381B2 (ja) | 多発性骨髄腫を治療するための薬物の組み合わせ | |
| RU2013131004A (ru) | Комбинация (а) ингибитора фосфоинозит-3-киназы и (б) модулятора пути ras/raf/mek | |
| RU2020142739A (ru) | Ингибиторы mdm2 и их комбинации | |
| EP4442321A3 (en) | Methods of treating sjögren's syndrome using a bruton's tyrosine kinase inhibitor | |
| EA200800161A1 (ru) | Новые фармацевтические композиции с модифицированным высвобождением и способ получения таких композиций | |
| JP2018168191A5 (https=) | ||
| JP2005538099A5 (https=) | ||
| HRP20100577T1 (hr) | Uporaba agomelatina za dobivanje lijeka s ciljem liječenja općeg poremećaja anksioznosti | |
| JP2012236857A5 (https=) | ||
| RU2014144254A (ru) | Комбинированные продукты, содержащие ингибиторы тирозинкиназ, и их применение | |
| JP2014505107A5 (https=) | ||
| AR045289A1 (es) | Forma de dosificacion oral de liberacion controlada que comprende 4-(2-di-n-propilaminoetil) - 2(3h)-indolona (ropi-nirol) y uso de dicha forma de dosificacion para la elaboracion de un medicamento | |
| JP2005506982A5 (https=) | ||
| JP2015517523A5 (https=) | ||
| MX2021014774A (es) | Formulaciones de liberacion modificada y usos de las mismas. | |
| MX2024014626A (es) | Metodos de tratamiento de la urticaria cronica espontanea utilizando un inhibidor de la tirosina quinasa de bruton | |
| HRP20231036T1 (hr) | Upotreba braf inhibitora za liječenje kožnih reakcija | |
| JP2020529995A5 (https=) | ||
| CN103889409A (zh) | N-羟基-4-{2-[3-(n,n-二甲基氨基甲基)苯并呋喃-2-基羰基氨基]乙氧基}苯甲酰胺的给药方案 | |
| JP2020536048A5 (https=) | ||
| JP2019515010A5 (https=) | ||
| RU2015124954A (ru) | Фармацевтические комбинации |